Navigation Links
Vaxine Wins Line Honours With World's First Human Swine Flu Vaccine

ADELAIDE, Australia, July 22 /PRNewswire/ -- VAXINE Pty Ltd, a South Australian biotechnology company, has successfully undertaken the first ever human immunisations with a candidate swine flu vaccine.

"This represents a major breakthrough as it is the first administration to human subjects of a swine flu vaccine anywhere in the world," said Professor Nikolai Petrovsky, Vaxine's Research Director. "The swine influenza vaccine we are testing, unlike old-fashioned egg-based virus vaccines is based on state-of-the-art recombinant protein technology combined with our proprietary polysaccharide adjuvant system (Advax(TM))," he said.

"This cutting-edge design means that vaccines can be produced in record time, making this technology ideal for rapid vaccine production in pandemic situations," said Dr Peter Cooper, who with Prof. Petrovsky invented the key adjuvant component of the vaccine.

"Never before has a new influenza vaccine been delivered to the clinic so fast. It is extraordinary what has been achieved in less than 3 months since the virus was first identified," said Dr Dimitar Sajkov, one of the clinical investigators. "We are proud to have got this swine flu vaccine to the clinic ahead of rival vaccines from the large manufacturers."

"Whilst we must be cautious until the outcome of these studies are known, if successful then it signals the beginning of the end for old-fashioned egg-based vaccines," said Prof. Petrovsky. "This new approach offers major safety advantages over traditional influenza vaccines as it is free of viral contaminants and is safe for people with egg allergies."

This new swine flu vaccine includes Vaxine's Advax adjuvant that induces powerful influenza protection through anti-influenza antibodies, but also T-cells, key components of the body's defence against the influenza virus.

Clinical trials of the new vaccine are being conducted for Vaxine by Prof. David Gordon at Flinders Medical Centre, Adelaide, Australia and are targeting 300 healthy subjects aged 18-70 years. Vaxine last week won the AMP Innovation Award of the 2009 Telstra Business Awards. Vaxine's preclinical vaccine research is supported by grants from the US National Institute of Health.

       Media enquiries:

       Nikolai Petrovsky
       phone: +61(0)8 82044572
       cell: +61(0)413 131635

About Vaxine Pty Ltd

Established in 2002, Vaxine is an Australian-based biotechnology company specialising in vaccine development. Lead products in clinical trials include vaccines for seasonal and pandemic influenza (including 2009 H1N1 swine flu), Japanese encephalitis, hepatitis B, and bee sting allergy.

SOURCE Vaxine Pty Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards
2. Frost & Sullivan Honours Redsense Medical With the 2008 European Hemodialysis Emerging Company of the Year Award
3. Frost & Sullivan Honours GELITA for Developing European Health Ingredient of the Year
4. Mottram Honours His End of the HBA Great Australian Run challenge
5. Frost & Sullivan Honours Outstanding Achievements in Healthcare
6. Frost & Sullivan Honours LyondellBasell With Customer Value Enhancement Award
7. BODY WORLDS 2 & Breathe California Pair Up for Some Ash Kicking
8. BODY WORLDS 3 & The Story of the Heart Opens at the California Science Center, March 14, 2008
9. Museum Open Around the Clock - BODY WORLDS 2 and The Tech Host 40 Hour Marathon!
10. The Institute for Plastination Responds to the Bishop of Manchesters Media Blitz, Assertions, and Allegations About BODY WORLDS Anatomical Exhibition Coming to Manchester
11. Specimens in BODY WORLDS Exhibitions Stem Primarily from German Body Donation Program
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon ... programs, launches new Wimbledon Athletics Facebook page to educate the public, ... unsuspected cardiac abnormalities. About 2,000 people under the age of 25 die from ...
(Date:11/25/2015)... ... 25, 2015 , ... Smiles by Stevens is pleased to announce ... wrinkling. While many patients are aware of the benefits of Botox® in the treatment ... those suffering with discomfort, soreness, and pain as a result of Jaw Tension, TMJ ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... decades of music, friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled ... 5-6. , For 65 years, Brillianteen has been a treasured tradition ...
(Date:11/25/2015)... D.C. (PRWEB) , ... November 25, 2015 , ... Today, ... fatalities on our nation’s roadways has dropped below 10,000 for the first time since ... 10,076 in 2013. , According to data released by the National Highway Traffic Safety ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... I found that regular bras were incredibly uncomfortable," said an inventor from Bronx, ... bra." , She developed the patent-pending RECOVERY BRA for added comfort and support. ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 2015  Thanks to a donor with a personal ... Center,s Sister Diane Grassilli Center for Women,s Health now ... San Francisco . Fred ... with a gift of $617,320 that allowed the Center ... Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or ... today that the first patient has been enrolled in ... treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... 1/2 clinical trial, ESSA intends to demonstrate the safety, ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... new market research report "Spine Biologics Market by Product Type ... Type (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), ... by MarketsandMarkets, the global market was valued at $1.90 Billion ... 2020, at a CAGR of 4.4% during the forecast period ...
Breaking Medicine Technology: